Novo Nordisk A/S

Initial read: constructive on franchise durability, cautiously constructive on valuation. Novo is no longer the uncomplicated hypergrowth obesity story of 2021–24.

1. The investment case has shifted from scarcity and manufacturing capacity to durability: how much economic value semaglutide can retain as U.S. pricing falls, Lilly takes share and obesity treatment broadens across products, channels and price points. The franchise remains unusually strong.
2. Semaglutide combines global scale with cardiovascular, renal, heart-failure, MASH and obesity evidence, while oral Wegovy provides a commercially available route into a substantially undertreated market. The stock thesis is less settled.
3. H1 2026 adjusted sales and operating profit grew only 2% at constant exchange rates, and full-year guidance allows both to decline by as much as 6%. At $38.80 on September 25, the ADR was down approximately 24% year to date, 19% over three months and 31% over one year.
4. The shares trade at roughly 9–10x 2025 adjusted earnings and about 8x 2025 EBITDA. That is optically inexpensive, but neither trailing earnings nor current free cash flow is a complete measure of normalized value.
5. PP&E capital expenditure rose from approximately DKK 6 billion in 2021 to DKK 60 billion in 2025 and remains near DKK 55 billion in 2026 as Novo adds API, fill-finish, oral and packaging capacity. Management expects spending to decline, creating a potentially important cash-conversion tailwind.
6. We would not add the capex decline mechanically to free cash flow: utilization, pricing and the return earned on the enlarged asset base matter as much as the spending level. The current valuation does not require a return to hypergrowth.
7. It does require the existing earnings base to remain durable—roughly, sustained low- to mid-single-digit consolidated growth, high operating margins and capital intensity that normalizes without leaving excess capacity. Oral Wegovy is the decisive current commercial test.
8. Its rapid prescription uptake demonstrates demand, but persistence, payer versus self-pay mix, realized net price and injectable cannibalization determine incremental value. CagriSema increasingly looks like franchise defence and lifecycle extension rather than the principal source of upside.
9. Zenagamtide is more important to the long-duration thesis because a successful oral and injectable GLP-1/amylin platform could rebuild differentiation as semaglutide matures. Novo has earned active due diligence after the derating; a higher-conviction view requires a channel-level revenue model, explicit product cannibalization and evidence that the capacity cycle produces both stronger cash conversion and acceptable returns on invested capital.